CannabisNewsBreaks – Jupiter Wellness Inc. (NASDAQ: JUPW) Initiates Clinical Trial for CBD-Based Therapeutic Candidate – CaniDermRx

November 13, 2020 13:02:27

Jupiter Wellness (NASDAQ: JUPW), a leading developer of cannabidiol (“CBD”) based therapeutics and wellness products, today announced its initiation of an exploratory clinical study of CaniDermRx. Jupiter’s prescription topical cream candidate, CaniDermRx, combines CBD and aspartame as its active ingredients in the treatment of first degree burns. While, to Jupiter’s knowledge, no double-blind, randomized controlled study has demonstrated efficacy of a CBD-aspartame product in the treatment of burns, CaniDermRx may be effective in this indication based on its dual mechanisms of action. “We are pleased to commence this clinical study in what is now our second indication for our CBD-based prescription therapeutic candidate CaniDermRx,” said Jupiter CEO Brian John. “As the number of burn cases is increasing worldwide, we are eager to explore the healing potential of CaniDermRx’s dual mechanisms of action for this patient population. Data resulting from the study would be included in an Investigational New Drug (‘IND’) application that we intend to file with the FDA for Phase I or II studies in the U.S.”

To view the full press release, visit

About Jupiter Wellness Inc.

Jupiter Wellness is a leading developer of cannabidiol (“CBD”) based medical therapeutics and wellness products. The company’s clinical pipeline of prescription CBD-enhanced skin care therapeutics address indications including eczema, burns, herpes cold sores, and skin cancer. Jupiter generates revenues from a growing line of proprietary over-the-counter skincare products including its flagship CaniSun(TM) sunscreen and other wellness brands sold through its robust distribution platform. For more information, visit the company’s website at

NOTE TO INVESTORS: The latest news and updates relating to JUPW are available in the company’s newsroom at

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only)

For more information please visit

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published:

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
303.498.7722 Office

CannabisNewsWire is part of the InvestorBrandNetwork.